Artboard 1

OpenBiome Webinar

On August 9th 2022, we hosted a live Q&A featuring members of the University of Minnesota (UMN) Microbiota Therapeutics Program and the American Gastroenterological Association (AGA). The Q&A covered investigational FMT preparations manufactured by UMN and how your site can join the AGA FMT registry to support long-term research.  

Key takeaways and an FAQ are shared below. 


Key Takeaways

  • Mission_Icon3

    OpenBiome will continue distributing UMN-manufactured investigational FMT for patients suffering from recurrent C. difficile (rCDI) not responding to standard therapies. To access this material, a new registration form must be completed. This applies to all sites, even if you have an existing OpenBiome agreement. 

  • An illustration of the OpenBiome supply chain

    Emergency Access Restriction Lifted: OpenBiome’s partnership with UMN has enabled us to lift the ‘emergency only’ shipping policy that was in place since August 2021. If you have patients that are eligible for an investigational FMT to treat rCDI, you may place an order without applying for emergency access.   

  • NextSteps

    Plans to Expand On-hand Inventory: As we have ramped up operations, we expanded access by allowing sites to maintain on-hand inventory. Partner sites can now maintain an inventory of up to 5 units of investigational FMT. 

Frequently Asked Questions about UMN-Manufactured Investigational FMT


Frequently Asked Questions about AGA FMT National Registry

Scroll To Top